Chinook Therapeutics (NASDAQ:KDNY) announced its quarterly earnings results on Tuesday. The company reported ($1.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.82), MarketWatch Earnings reports. Chinook Therapeutics had a negative net margin of 215.80% and a negative return on equity of 112.72%.
KDNY opened at $14.75 on Thursday. The firm’s fifty day moving average is $16.88. Chinook Therapeutics has a 52 week low of $10.50 and a 52 week high of $21.68. The firm has a market capitalization of $621.83 million, a price-to-earnings ratio of -4.10 and a beta of 0.26.
A number of analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Chinook Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 11th. Bloom Burton restated a “buy” rating on shares of Chinook Therapeutics in a research report on Monday, March 22nd. Wedbush started coverage on shares of Chinook Therapeutics in a research report on Wednesday, January 6th. They set an “outperform” rating and a $28.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on shares of Chinook Therapeutics in a report on Wednesday, December 9th. They issued an “overweight” rating and a $31.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Chinook Therapeutics presently has an average rating of “Buy” and a consensus target price of $28.29.
Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases.
Featured Article: What is the return on assets (ROA) ratio?
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.